3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
10
INDUSTRY
10
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Tumor-Agnostic
1
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
Conditions
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
12
Rituximab
9
fludarabine
6
Prednisone
5
Vinorelbine
4
Vincristine
4
Epirubicin
4
zanubrutinib
3
Nivolumab
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Gemcitabine
3
Drug Therapy
3
pegylated granulocyte colony-stimulating factor
2
fludarabine phosphate
2
Thiotepa
2
Metformin
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Doxorubicin
2
Cytarabine
2
Bortezomib
2
treosulfan
1
plerixafor
1
pegfilgrastim
1
parsaclisib
1
obinutuzumab
1
nilotinib
1
liposomal doxorubicin
1
ivarmacitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
durvalumab
×
Lymphoid
×
Clear all
NCT03610061
2024-04-12
RaDD
Austin Health
Phase 1
Completed
34 enrolled